Nuclear medicine

SHINE Supercell Completes Testing Ahead of Shipment to U.S.

Retrieved on: 
Wednesday, October 12, 2022

BARCELONA, Spain, Oct. 12, 2022 /PRNewswire/ -- SHINE Technologies and Von Gahlen International today announced that SHINE's supercell has passed factory acceptance testing. Completion of that testing means the supercell, a bank of 10 hot cells, is now being prepared for final shipment to The Chrysalis, SHINE's large-scale medical isotope production facility in Janesville, Wisconsin.

Key Points: 
  • BARCELONA, Spain, Oct. 12, 2022 /PRNewswire/ -- SHINE Technologies and Von Gahlen International today announced that SHINE's supercell has passed factory acceptance testing.
  • Completion of that testing means the supercell, a bank of 10 hot cells, is now being prepared for final shipment to The Chrysalis, SHINE's large-scale medical isotope production facility in Janesville, Wisconsin.
  • The supercell will house key processes of medical isotope production , including the extraction, purification and packaging of molybdenum-99 (Mo-99) .
  • We look forward to continuing to work with SHINE and share in their vision for a safer, healthier, and cleaner world."

SHINE Supercell Completes Testing Ahead of Shipment to U.S.

Retrieved on: 
Wednesday, October 12, 2022

BARCELONA, Spain, Oct. 12, 2022 /PRNewswire/ -- SHINE Technologies and Von Gahlen International today announced that SHINE's supercell has passed factory acceptance testing. Completion of that testing means the supercell, a bank of 10 hot cells, is now being prepared for final shipment to The Chrysalis, SHINE's large-scale medical isotope production facility in Janesville, Wisconsin.

Key Points: 
  • BARCELONA, Spain, Oct. 12, 2022 /PRNewswire/ -- SHINE Technologies and Von Gahlen International today announced that SHINE's supercell has passed factory acceptance testing.
  • Completion of that testing means the supercell, a bank of 10 hot cells, is now being prepared for final shipment to The Chrysalis, SHINE's large-scale medical isotope production facility in Janesville, Wisconsin.
  • The supercell will house key processes of medical isotope production , including the extraction, purification and packaging of molybdenum-99 (Mo-99) .
  • "After seeing the supercell progress during recent trips to Europe, I am excited that it has passed testing and is on its way to Wisconsin.

BWX Technologies to Announce Third Quarter 2022 Results on Monday, November 7

Retrieved on: 
Wednesday, October 12, 2022

BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing third quarter 2022 results on Monday, November 7, 2022, after market close and will host a conference call at 5:00 p.m. EST.

Key Points: 
  • BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing third quarter 2022 results on Monday, November 7, 2022, after market close and will host a conference call at 5:00 p.m. EST.
  • Listen-only participants are encouraged to participate and view the supporting presentation via the Internet at www.bwxt.com /investors.
  • The dial-in numbers for participants are (U.S.) 1-844-200-6205, (Canada) 1-833-950-0062 and (International) +1-929-526-1599; access code: 461827.
  • At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven.

Eclipse and Mayo Clinic Create Nucleus RadioPharma to Better Serve Cancer Patients

Retrieved on: 
Wednesday, October 12, 2022

ROCHESTER, Minn., and PALO ALTO, Calif., Oct. 12, 2022 /PRNewswire/ -- Eclipse, a venture capital firm investing in the digital transformation of the world's physical industries, and Mayo Clinic, a leading nonprofit health organization, today announced the creation and seed funding of Nucleus RadioPharma, a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new therapies.

Key Points: 
  • We believe that radiopharmaceuticals are highly innovative new therapies with tremendous potential to help cancer patients," said Cheryl Willman, M.D., Executive Director of Mayo Clinic Cancer Programs.
  • "The collaboration with Nucleus RadioPharma will provide enhanced manufacturing capabilities so Mayo Clinic can rapidly deliver radiopharmaceuticals, empowering us to better serve our patients today, and enabling the development and clinical testing of novel targeted radiotherapies in the future."
  • "We are building Nucleus RadioPharma to be the glue that connects hospitals with radiopharmaceutical developers, providing new hope for our cancer patients," said Geoff Johnson, M.D., Ph.D., Chair of Nuclear Medicine at Mayo Clinic.
  • Visit the Mayo Clinic Comprehensive Cancer Center Blog for news, information and stories from Mayo Clinic's cancer experts and patients.

Global Nuclear Medicine Equipment Market Report to 2030 - Featuring Siemens Healthineers, Fujifilm Holdings, Canon and Digirad Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 12, 2022

The growth of the nuclear medicine equipment market is driven by the availability of high-quality equipment, rise in the adoption of nuclear medicine equipment, and the emergence of innovative & advanced equipment.

Key Points: 
  • The growth of the nuclear medicine equipment market is driven by the availability of high-quality equipment, rise in the adoption of nuclear medicine equipment, and the emergence of innovative & advanced equipment.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nuclear medicine equipment market analysis from 2020 to 2030 to identify the prevailing nuclear medicine equipment market opportunities.
  • In-depth analysis of the nuclear medicine equipment market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global nuclear medicine equipment market trends, key players, market segments, application areas, and market growth strategies.

EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility

Retrieved on: 
Tuesday, October 11, 2022

The equipment, worth several million USD, will be used by NorthStar in Beloit, Wisconsin, to produce commercial-scale quantities of n.c.a.

Key Points: 
  • The equipment, worth several million USD, will be used by NorthStar in Beloit, Wisconsin, to produce commercial-scale quantities of n.c.a.
  • The manufacturing process for these advanced radiopharmaceuticals requires innovative solutions and equipment to enable routine large-scale commercial production of Ac-225.
  • Ac-225 utilizing our electron accelerator technology that is environmentally preferable and non-uranium based, said Stephen Merrick, Chief Executive Officer of NorthStar Medical Radioisotopes.
  • NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radioisotopes and radiopharmaceuticals.

Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility

Retrieved on: 
Tuesday, October 11, 2022

The equipment, worth several million USD, will be used by NorthStar in Beloit, Wisconsin, to produce commercial-scale quantities of n.c.a.

Key Points: 
  • The equipment, worth several million USD, will be used by NorthStar in Beloit, Wisconsin, to produce commercial-scale quantities of n.c.a.
  • The manufacturing process for these advanced radiopharmaceuticals requires innovative solutions and equipment to enable routine large-scale commercial production of Ac-225.
  • Ac-225 utilizing our environmentally preferable and non-uranium based electron accelerator technology, said Stephen Merrick, Chief Executive Officer of NorthStar Medical Radioisotopes.
  • NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radioisotopes and radiopharmaceuticals.

New Momentum Magnetic Particle Imaging Scanner Has Been Installed in Los Angeles County

Retrieved on: 
Tuesday, October 11, 2022

The scanner will be housed at City of Hope's pre-clinical research facilities in Los Angeles.

Key Points: 
  • The scanner will be housed at City of Hope's pre-clinical research facilities in Los Angeles.
  • The Momentum MPI scanner enables preclinical testing of the imaging protocols and cell therapies being translated to clinical research applications by capturing pathophysiology currently invisible to traditional imaging techniques.
  • While Magnetic Insight has shipped pre-clinical imagers worldwide, they are now scaling MPI technology to clinical scale.
  • Magnetic Insight has pioneered magnetic particle imaging (MPI), a new diagnostic and monitoring technology that transforms medical imaging.

Insights on the Nuclear Imaging Equipment Market in Saudi Arabia to 2027 - Rising Prevalence of Chronic Diseases and the Increasing Number of Cancer Patients is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022

The "Saudi Arabia Nuclear Imaging Equipment Market, By Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Application (Oncology, Cardiology, Neurology, Others), By End User, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Saudi Arabia Nuclear Imaging Equipment Market, By Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Application (Oncology, Cardiology, Neurology, Others), By End User, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Saudi Arabia nuclear imaging equipment market is anticipated to grow at a formidable rate in the forecast period, 2023-2027.
  • Rise in prevalence of chronic diseases and the growing number of cancer patients are the primary factors driving the demand for Saudi Arabia nuclear imaging equipment market.
  • Organ and tissue functions are studied using nuclear imaging technology, which creates images of the organs and tissues at the nuclear level.

EANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline

Retrieved on: 
Monday, October 10, 2022

Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.

Key Points: 
  • Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.
  • The breadth of our innovative theranostic pipeline is demonstrative of our commitment and progress towards advancing nuclear medicine across a range of indications."
  • EANM presentation details are as follows:
    Chairperson: Professor Wolfgang Fendler- Vice Chair, Clinic for Nuclear Medicine, EssenUniversity Hospital, Essen, Germany.
  • -Professor JochenWalz - Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France.